BioMarin Pharmaceutical Inc. is still on track to launch the first gene therapy for hemophilia A in the US later this year, but acknowledged during its first quarter sales and earnings call on 29 April that the commercial dynamics are uncertain because of the COVID-19 outbreak.
Management unveiled a new brand name for valoctocogene roxaparvovec, which will be marketed as Roctavian. BioMarin is anticipating FDA action on the biologics licensing application for the gene therapy by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?